Three novel therapies will contribute to the growth of the BPH therapeutics market, including the launch of Nymox’s novel first-in-class therapy, NX-1207.
![Global Therapeutics Market for Benign Prostatic Hyperplasia to Reach $4.9 Billion By 2024 Global Therapeutics Market for Benign Prostatic Hyperplasia to Reach $4.9 Billion By 2024](https://images.medindia.net/health-images/1200_1000/dollar-note-1.jpg)
Valentina Gburcik, GlobalDatas Director of Cardiovascular & Metabolic Disorders, states that three novel therapies will contribute to the growth of the BPH therapeutics market, including the launch of Nymox’s novel first-in-class therapy, NX-1207, in the US and Europe in 2017 and 2019, respectively.
Gburcik said, “NX-1207 is a direct prostatic injection indicated for patients with moderate-to-severe BPH. It offers an increased safety profile and improved efficacy in comparison with currently available BPH therapies, and lasts for a mean duration of 3.5 years after a single injection.”
The drug will also be priced at a premium compared with current products, meaning that it will contribute significantly towards the anticipated market expansion following its launch.
The director adds that an increasing number of diagnosed BPH cases worldwide, resulting from an aging male population, will further drive the market over the forecast period.
However, several barriers will hinder any further growth in the BPH therapy space, according to GlobalData report.
Advertisement
This will be exacerbated by a lack of pipeline therapies for mild-to-moderate BPH symptoms, leaving a significant portion of the patient population underserved, concluded the director.
Advertisement